These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 35514988)

  • 21. Intravenous immunoglobulin for myasthenia gravis.
    Gajdos P; Chevret S; Toyka KV
    Cochrane Database Syst Rev; 2012 Dec; 12(12):CD002277. PubMed ID: 23235588
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sensitivity of MG-ADL for generalized weakness in myasthenia gravis.
    de Meel RHP; Raadsheer WF; van Zwet EW; Verschuuren JJGM; Tannemaat MR
    Eur J Neurol; 2019 Jun; 26(6):947-950. PubMed ID: 30417962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quality of life in 188 patients with myasthenia gravis in China.
    Yang Y; Zhang M; Guo J; Ma S; Fan L; Wang X; Li C; Guo P; Wang J; Li H; Li Z
    Int J Neurosci; 2016; 126(5):455-62. PubMed ID: 26000922
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension.
    Meisel A; Annane D; Vu T; Mantegazza R; Katsuno M; Aguzzi R; Frick G; Gault L; Howard JF;
    J Neurol; 2023 Aug; 270(8):3862-3875. PubMed ID: 37103755
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Eculizumab improves fatigue in refractory generalized myasthenia gravis.
    Andersen H; Mantegazza R; Wang JJ; O'Brien F; Patra K; Howard JF;
    Qual Life Res; 2019 Aug; 28(8):2247-2254. PubMed ID: 30905021
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical efficacy and immunological impact of tacrolimus in Chinese patients with generalized myasthenia gravis.
    Zhao CB; Zhang X; Zhang H; Hu XQ; Lu JH; Lu CZ; Xiao BG
    Int Immunopharmacol; 2011 Apr; 11(4):519-24. PubMed ID: 21195813
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Phase 3 Multicenter, Prospective, Open-Label Efficacy and Safety Study of Immune Globulin (Human) 10% Caprylate/Chromatography Purified in Patients with Myasthenia Gravis Exacerbations.
    Karelis G; Balasa R; De Bleecker JL; Stuchevskaya T; Villa A; Van Damme P; Lagrange E; Heckmann JM; Nicolle M; Vilciu C; Bril V; Mondou E; Griffin R; Chen J; Henriquez W; Garcia B; Camprubi S; Ayguasanosa J
    Eur Neurol; 2019; 81(5-6):223-230. PubMed ID: 31655810
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma exchange for myasthenia gravis.
    Gajdos P; Chevret S; Toyka K
    Cochrane Database Syst Rev; 2002; 2002(4):CD002275. PubMed ID: 12519572
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prospective cohort study evaluating efficacy and safety of efgartigimod in Chinese generalized myasthenia gravis patients.
    Wang P; Zhang B; Yin J; Xi J; Tan Y; Gao F; Zeng F; Chang T; Zhou H; Liang H; Zhao Z; Yang H; Zhao C; Huang S
    Front Neurol; 2024; 15():1407418. PubMed ID: 38966082
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Myasthenia Gravis Impairment Index: Sensitivity for Change in Generalized Muscle Weakness.
    de Meel RHP; Barnett C; Bril V; Tannemaat MR; Verschuuren JJGM
    J Neuromuscul Dis; 2020; 7(3):297-300. PubMed ID: 32250313
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Subcutaneous immunoglobulin in myasthenia gravis exacerbation: A prospective, open-label trial.
    Beecher G; Anderson D; Siddiqi ZA
    Neurology; 2017 Sep; 89(11):1135-1141. PubMed ID: 28814461
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efgartigimod in generalized myasthenia gravis: A real-life experience at a national reference center.
    Frangiamore R; Rinaldi E; Vanoli F; Andreetta F; Ciusani E; Bonanno S; Maggi L; Gallone A; Colasuonno A; Tramacere I; Cheli M; Pinna A; Mantegazza R; Antozzi C
    Eur J Neurol; 2024 Apr; 31(4):e16189. PubMed ID: 38164996
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravenous immunoglobulin for myasthenia gravis.
    Gajdos P; Chevret S; Toyka K
    Cochrane Database Syst Rev; 2003; (2):CD002277. PubMed ID: 12804431
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation between myasthenia gravis-activities of daily living (MG-ADL) and quantitative myasthenia gravis (QMG) assessments of anti-acetylcholine receptor antibody-positive refractory generalized myasthenia gravis in the phase 3 regain study.
    Vissing J; O'Brien F; Wang JJ; Howard JF
    Muscle Nerve; 2018 Aug; 58(2):E21-E22. PubMed ID: 29684239
    [No Abstract]   [Full Text] [Related]  

  • 35. Tacrolimus Improves Symptoms of Children With Myasthenia Gravis Refractory to Prednisone.
    Liu C; Gui M; Cao Y; Lin J; Li Y; Ji S; Bu B
    Pediatr Neurol; 2017 Dec; 77():42-47. PubMed ID: 29074055
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cigarette Smoking and Activities of Daily Living in Ocular Myasthenia Gravis.
    Gratton SM; Herro AM; Feuer WJ; Lam BL
    J Neuroophthalmol; 2016 Mar; 36(1):37-40. PubMed ID: 26457691
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Fluoroquinolone associated myasthenia gravis exacerbation: clinical analysis of 9 cases].
    Wang SH; Xie YC; Jiang B; Zhang JY; Qu Y; Zhao Y; Li Y; Qiao SS; Xu CL
    Zhonghua Yi Xue Za Zhi; 2013 May; 93(17):1283-6. PubMed ID: 24029473
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial.
    Howard JF; Nowak RJ; Wolfe GI; Freimer ML; Vu TH; Hinton JL; Benatar M; Duda PW; MacDougall JE; Farzaneh-Far R; Kaminski HJ; ; Barohn R; Dimachkie M; Pasnoor M; Farmakidis C; Liu T; Colgan S; Benatar MG; Bertorini T; Pillai R; Henegar R; Bromberg M; Gibson S; Janecki T; Freimer M; Elsheikh B; Matisak P; Genge A; Guidon A; David W; Habib AA; Mathew V; Mozaffar T; Hinton JL; Hewitt W; Barnett D; Sullivan P; Ho D; Howard JF; Traub RE; Chopra M; Kaminski HJ; Aly R; Bayat E; Abu-Rub M; Khan S; Lange D; Holzberg S; Khatri B; Lindman E; Olapo T; Sershon LM; Lisak RP; Bernitsas E; Jia K; Malik R; Lewis-Collins TD; Nicolle M; Nowak RJ; Sharma A; Roy B; Nye J; Pulley M; Berger A; Shabbir Y; Sachdev A; Patterson K; Siddiqi Z; Sivak M; Bratton J; Small G; Kohli A; Fetter M; Vu T; Lam L; Harvey B; Wolfe GI; Silvestri N; Patrick K; Zakalik K; Duda PW; MacDougall J; Farzaneh-Far R; Pontius A; Hoarty M
    JAMA Neurol; 2020 May; 77(5):582-592. PubMed ID: 32065623
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
    Howard JF; Bril V; Vu T; Karam C; Peric S; Margania T; Murai H; Bilinska M; Shakarishvili R; Smilowski M; Guglietta A; Ulrichts P; Vangeneugden T; Utsugisawa K; Verschuuren J; Mantegazza R;
    Lancet Neurol; 2021 Jul; 20(7):526-536. PubMed ID: 34146511
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravenous immunoglobulin for myasthenia gravis.
    Gajdos P; Chevret S; Toyka K
    Cochrane Database Syst Rev; 2006 Apr; (2):CD002277. PubMed ID: 16625559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.